Welcome to our dedicated page for MEDLINE SEC filings (Ticker: MDLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medline Inc. (MDLN) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures as it becomes and operates as a publicly traded company. Medline has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to an initial public offering of its common stock, and it has announced the effectiveness of that registration statement and the pricing and closing of an upsized initial public offering of Class A common stock on the Nasdaq Global Select Market.
As Medline continues to report as a public company, this page will surface filings such as registration statements, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, when available. These documents are where Medline provides detailed information about its med-surg products and supply chain solutions, its two operating segments (Medline Brand and Supply Chain Solutions), its revenue sources, risk factors and other material business information.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents in plain language. Instead of reading an entire registration statement or future 10-K, users can rely on AI-generated highlights that point to major business updates, capital structure changes, and disclosures related to Medline’s role as what it describes as the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products.
The filings page also connects users to real-time updates from the SEC’s EDGAR system as new Medline filings are posted. Over time, this includes information on executive and insider transactions reported on Form 4, as well as proxy statements that describe governance and compensation matters. Together, these tools allow users to follow MDLN’s regulatory history and understand how Medline presents its business and risks in official SEC documents.
Medline Inc. Chief Human Resources Officer Christopher P. Shryock reported equity compensation awards rather than open‑market trades. He received 11,903 shares of Class A common stock as a restricted stock unit grant, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning March 1, 2027.
He also acquired 496,049 and 40,638 Incentive Units of Medline Holdings, LP, held indirectly through Medline Management Aggregator LLC. These Incentive Units are profit interests with economics similar to stock appreciation rights, convertible into common units of Medline Holdings, LP and then exchangeable one‑for‑one into Class A common stock, subject to vesting schedules described in the footnotes.
Medline Inc. Chief Financial Officer Michael B. Drazin reported a series of equity awards and ownership changes. On March 5, 2026, he received a grant of 25,788 restricted stock units of Class A common stock at no cash cost, with 25% vesting on June 15, 2026 and the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
Earlier, on December 16, 2025, interests in Medline Holdings, LP were reclassified in connection with Medline’s initial public offering. In that reclassification and related awards, entities associated with Drazin acquired 486,028 Common Units of Medline Holdings, LP and corresponding 486,028 shares of Class B common stock, as well as multiple blocks of Incentive Units of Medline Holdings, LP held indirectly through Medline Management Aggregator LLC. Common Units are exchangeable one-for-one into Class A common stock under an exchange agreement, while Class B shares carry voting rights but no economic value and are cancelled when Common Units are exchanged.
Medline Inc. Chief Product Officer Amanda H. Laabs reported equity awards rather than open‑market trades. On March 5, 2026, she acquired 25,788 shares of Class A common stock at $0.00 per share as a grant of restricted stock units. According to the disclosure, 25% of these RSUs vest on June 15, 2026, with the remaining 75% vesting in three equal annual installments beginning on March 1, 2027.
The filing also details prior awards from December 16, 2025, including 251,070 Common Units of Medline Holdings, LP and several tranches of Incentive Units, all acquired at $0.00 per unit. These units are held indirectly through Medline Management Aggregator LLC and can be exchanged into Common Units, which in turn are exchangeable on a one‑for‑one basis for Class A common stock under an exchange agreement. Class B common stock, issued one share for each Common Unit, carries voting rights but no economic value and is cancelled upon exchange into Class A shares.
Medline Inc. Chief Legal Officer Alexander M. Liberman reported multiple equity awards that increase his direct and indirect ownership interests. On March 5, 2026, he received 11,903 shares of Class A common stock for no cash consideration, described as restricted stock units that vest over time.
Earlier awards dated December 16, 2025 include Class B common stock, Common Units of Medline Holdings, LP and Incentive Units of Medline Holdings, LP, many held indirectly through a trust where his spouse is trustee and through Medline Management Aggregator LLC. These Common Units are exchangeable one-for-one into Class A common stock under an exchange agreement, while Incentive Units are profit interests that can convert into Common Units when vested and in the money.
Medline Inc. is registering 75,000,000 shares of its Class A common stock for resale by the selling stockholders. The prospectus states the public offering price is $41.00 per share and that Medline will receive no proceeds from these sales. The underwriters have a 30-day option to purchase up to an additional 11,250,000 shares. The prospectus cites 811,647,534 shares outstanding as of February 23, 2026 and references an as-reported closing price of $42.88 on March 4, 2026.
Medline Inc. is registering 75,000,000 shares of Class A common stock for resale by selling stockholders in a secondary offering. The underwriters may purchase up to an additional 11,250,000 shares from these holders. Medline’s Class A stock trades on Nasdaq under the symbol “MDLN,” and the closing price on February 26, 2026 was $48.89 per share.
Medline will not receive any proceeds from the sale; certain selling stockholders will first exchange partnership Common Units for Class A shares, reflecting the company’s UP‑C structure. As of February 23, 2026, 811,647,534 shares of Class A common stock were outstanding. For 2025, Medline reported net sales of $28.4 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.5 billion, supported by a large med‑surg product portfolio and Prime Vendor distribution model.
Medline Inc. files an annual report outlining its business, structure, and key risks following its 2025 IPO. The company is a Delaware holding company whose sole material assets are equity interests in Medline Holdings, LP, which it controls as general partner.
Medline reports two main segments: Medline Brand, offering about 190,000 proprietary med‑surg products, and Supply Chain Solutions, offering about 145,000 third‑party products and optimization services. A Prime Vendor model with multi‑year contracts and a large U.S. distribution network underpins its strategy and supports a high reported retention rate.
The filing highlights extensive regulatory oversight, substantial indebtedness, and global operational, cybersecurity, and data‑privacy risks. As of December 17, 2025, non‑affiliate Class A common stock had an estimated market value of about $13.0 billion, and as of February 23, 2026 there were 811,647,534 Class A and 502,045,878 Class B shares outstanding.
Medline Inc. reported strong 2025 sales growth but weaker margins while completing its IPO. Full-year net sales rose to $28.4 billion, up 11.5% from $25.5 billion, with Organic Sales up 10.5%. Adjusted EBITDA increased 3.2% to $3.5 billion, while net income slipped 3.6% to $1.2 billion as tariffs and higher operating costs weighed on profitability.
For the fourth quarter, net sales grew 14.8% to $7.8 billion, but net income fell 37.7% to $180 million and Adjusted EBITDA was essentially flat at $805 million. Medline completed its initial public offering, ended 2025 with $1.7 billion in operating cash flow and $1.3 billion in Free Cash Flow, and reduced net debt to $10.8 billion, lowering Net Leverage to 3.1x from 4.9x. For 2026, the company targets 8–9% Organic Sales growth and Adjusted EBITDA of $3.5–$3.6 billion.
Medline Inc. reported initial insider holdings for major investors Mozart Aggregator UNLV Holdco L.P. and Mozart Aggregator II UNLV Holdco L.P. The filing shows indirect ownership of Class A and Class B common stock and common units of Medline Holdings, L.P. Internal contributions among related Blackstone-affiliated entities moved these securities into the Holdco vehicles, but the notes state no Medline securities were purchased or sold in the market and that holders are subject to a lock-up agreement. Class B shares carry voting rights but no economic value and are paired one-for-one with common units that can be exchanged into Class A shares under an exchange agreement.